The 19th International Reid Bioanalytical Forum

 The 19th International Reid Bioanalytical Forum was attended by over 120 participants. The Forum divided into approximately eight broad topics, although not always in the same session. The meeting commenced with a discussion on metabolites in safety testing, with emphasis on enabling technologies and philosophies. This was followed by a variety of regulatory-based issues initiated by Brian Booth of the US FDA. The next day started with a review of developing technologies in LC–MS and some anecdotal troubleshooting experiences.  Interspersed among the sessions were experiences with bioanalysis in the discovery environment, biomarker-based topics and the rapidly developing field of the...

To view this content, please register now for access

It's completely free